Jeff Bird, MD, PhD

Jeff Bird has been a life sciences investor for nearly 20 years at Sutter Hill Ventures. In 2019, Jeff formed BlueBird Ventures. He most recently served on the boards of 2 public companies, Portola Pharmaceuticals and Forty Seven, Inc. He served as Chief Executive Officer of Verinata Health, a developer of noninvasive prenatal diagnostics that was sold to Illumina in 2013. Prior to Sutter Hill Ventures, he was an executive at Gilead Sciences for 12 years, most recently as Senior Vice President of Business Operations, which included global sales and marketing. Jeff received his MD and PhD in cancer biology from Stanford University School of Medicine and was also a Stanford University undergraduate.